Milestone moment for pediatric IBD care as integrative treatment gains clinical spotlight
This week marked a major milestone for Evinature and the future of pediatric IBD care. Our co-founder, Nir Salomon, presented the groundbreaking CurQD® Protocol at The Hospital for Sick Children (SickKids) in Toronto—one of the most prestigious pediatric medical and research institutions in the world.
The presentation highlighted the growing clinical and real-world evidence behind CurQD®, with particular attention to its application in children and adolescents living with Inflammatory Bowel Disease (IBD). As incidence rates continue to rise among pediatric populations, the need for safe, effective, and sustainable treatment alternatives has never been more urgent.
“Kids have their entire lives ahead of them. Helping them regain health early isn’t just treatment—it’s prevention. It’s setting the course for a lifetime,” Salomon shared.
Developed at Sheba Medical Center, CurQD® is a clinically validated, nutraceutical protocol based on precision doses of gut-directed curcumin. It has shown powerful anti-inflammatory effects with excellent safety profiles, even among younger and more sensitive patients. Its tiered design makes it adaptable to varying severities of IBD, offering a personalized approach that complements conventional care.
SickKids’ interest in the protocol signals an important shift: integrative, evidence-based nutraceuticals are being increasingly welcomed into the mainstream conversation—particularly where pediatric treatment options are limited or carry heavy side effect burdens.
This event stands as a testament to Evinature’s mission: to bridge modern clinical science with natural therapeutics, and to bring hope and healing to those who need it most—starting young.
Stay tuned for more updates as CurQD® continues its global journey into clinical practice and research institutions.
Evinature
